Connect with us

Hi, what are you looking for?

CE Mark

Biopix-T Gets CE Mark for Point-of-Care Platform, Molecular SARS-CoV-2 Test

The Greek molecular diagnostic company’s Pebble analysis device relies on real-time quantitative colorimetric loop-mediated isothermal amplification.

Biopix-T Gets CE Mark for Point-of-Care Platform, Molecular SARS-CoV-2 Test

Greek molecular diagnostics company Biopix-T has secured a CE-IVD mark for its SARS-CoV-2 test, called COV19 qcLAMP kit, and for the point-of-care Pebble qcLAMP Platform it runs on.

Based in Heraklion, the capital of the island of Crete, Biopix-T was founded in 2019 to commercialize technology developed by researchers at the Institute of Molecular Biology and Biotechnology of the Foundation for Research and Technology – Hellas, or IMBB-FORTH.

The company’s analysis device relies on real-time quantitative colorimetric loop-mediated isothermal amplification, or qcLAMP, and is being positioned as a rapid, precise alternative to real-time PCR, the standard technique for molecular SARS-CoV-2 testing.

Biopix-T obtained the CE-IVD marks for the assay and device under the European In Vitro Diagnostic Directive, which will remain in force until May 2022, when Europe transitions to the newer In Vitro Diagnostic Regulation.

According to the firm, its test has a turnaround time of 30 minutes. It relies on nasal, saliva, or pharyngeal swab specimens collected from patients. The handheld device weighs less than 300 grams and can be used to test samples at the point of need.

CEO George Papadakis said in a statement that the device could be used to provide results to “all points of care as well as other points of interest, such as airports, cruise ships, companies, community services, but also hotels, border entry points, or immigration hot-spots.”

To support the product development and certification process, Biopix-T secured an undisclosed amount of initial funding from the Patras Science Park, located outside of Patras, Greece, as well as about €1.5 million ($1.7 million) in a round led by Athens-based Metavallon VC and Bulgaria’s Eleven VC. The company also carried out a clinical study of its test with partners at the University Hospital of Heraklion in Crete, as well as assessment studies with the Hellenic Pasteur Institute of Athens and a private Swiss lab.

Additional clinical studies, supported by a €2.4 million European Horizon 2020 grant awarded last year, are underway.

Seen on GenomeWeb: Article Link

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Emerging Technologies

There is no going backward, no one wants to eliminate therapeutic and catheter options, innovation drives better access and outcomes, so what is the...

Digital Health

The company offers the program as a bundle of devices, supplies and services and delivered as a 30-day subscription to eliminate upfront costs.

Digital Health

Lexington, Massachusetts-based Fractyl Health (formerly Fractyl Laboratories) can now increase the sample size of the Revitalize-1 trial (formerly Revita-T2Di trial) from 288 to 420.


This robotic assisted procedure is the first intervention within a clinical study carried out by CathBot; a joint venture between Robocath and MedBot (the...

You May Also Like

Artificial Intelligence

Today & Tomorrow: Digital Solutions in HealthTech Plug “digital healthcare solutions” into Google, and the results are clear: digital tools have taken the healthcare...


In Delray Beach, Florida, an emerging biopharma company, Cyrano Therapeutics, is planning a clinical trial using approved theophylline via a new intranasal pathway of...

Artificial Intelligence

Joe Mullings discusses the Microbot – Liberty robotic platform with Harel Gadot and how a new category of surgical robotics creates a new entry...

Digital Health

The sky’s the limit for HealthTech PR and looking past traditional strategies to nontraditional avenues for engagement will allow agencies to stand out.